Diplomat Pharmacy Inc (NYSE:DPLO) shot up 5.2% on Monday . The company traded as high as $19.77 and last traded at $19.51. 731,523 shares traded hands during mid-day trading, a decline of 25% from the average session volume of 980,643 shares. The stock had previously closed at $18.54.
Several research firms have recently commented on DPLO. ValuEngine cut Diplomat Pharmacy from a “hold” rating to a “sell” rating in a research note on Wednesday, September 12th. Morgan Stanley upped their price target on Diplomat Pharmacy from $16.00 to $21.00 and gave the stock an “equal weight” rating in a research note on Tuesday, July 3rd. Finally, Leerink Swann restated an “outperform” rating and set a $33.00 price target on shares of Diplomat Pharmacy in a research note on Friday, June 22nd. One investment analyst has rated the stock with a sell rating, seven have issued a hold rating and six have issued a buy rating to the company’s stock. Diplomat Pharmacy presently has an average rating of “Hold” and a consensus price target of $26.64.
The company has a debt-to-equity ratio of 0.58, a current ratio of 0.91 and a quick ratio of 0.63. The company has a market capitalization of $1.44 billion, a P/E ratio of 22.07 and a beta of 1.13.
Diplomat Pharmacy (NYSE:DPLO) last released its quarterly earnings results on Monday, August 6th. The company reported $0.17 EPS for the quarter, missing the Thomson Reuters’ consensus estimate of $0.23 by ($0.06). Diplomat Pharmacy had a return on equity of 7.86% and a net margin of 0.06%. The company had revenue of $1.42 billion for the quarter, compared to analysts’ expectations of $1.42 billion. During the same quarter last year, the company earned $0.25 EPS. Diplomat Pharmacy’s revenue for the quarter was up 25.8% compared to the same quarter last year. Analysts forecast that Diplomat Pharmacy Inc will post 0.83 earnings per share for the current fiscal year.
In other Diplomat Pharmacy news, Director Philip R. Hagerman sold 209,367 shares of the stock in a transaction on Thursday, September 13th. The stock was sold at an average price of $19.07, for a total value of $3,992,628.69. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Philip R. Hagerman sold 57,500 shares of the stock in a transaction on Tuesday, September 11th. The stock was sold at an average price of $19.21, for a total value of $1,104,575.00. The disclosure for this sale can be found here. 24.70% of the stock is owned by corporate insiders.
A number of large investors have recently added to or reduced their stakes in DPLO. SG Americas Securities LLC purchased a new position in Diplomat Pharmacy in the first quarter worth $104,000. UBS Group AG raised its position in Diplomat Pharmacy by 186.4% in the first quarter. UBS Group AG now owns 8,491 shares of the company’s stock worth $171,000 after acquiring an additional 5,526 shares in the last quarter. United Services Automobile Association purchased a new position in Diplomat Pharmacy in the second quarter worth $210,000. D.A. Davidson & CO. purchased a new position in Diplomat Pharmacy in the second quarter worth $215,000. Finally, Xact Kapitalforvaltning AB purchased a new position in Diplomat Pharmacy in the second quarter worth $225,000. Hedge funds and other institutional investors own 80.89% of the company’s stock.
Diplomat Pharmacy Company Profile (NYSE:DPLO)
Diplomat Pharmacy, Inc operates as an independent specialty pharmacy in the United States. The company stocks, dispenses, and distributes prescriptions for various biotechnology and specialty pharmaceutical manufacturers. It also provides specialty infusion pharmacy, patient care coordination, clinical, compliance and persistency program, patient financial assistance, specialty pharmacy training/consulting, benefits investigation, prior authorization, risk evaluation and medication strategy, retail specialty, and hub services, as well as clinical and administrative support services to hospitals and health systems.
Receive News & Ratings for Diplomat Pharmacy Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Diplomat Pharmacy and related companies with MarketBeat.com's FREE daily email newsletter.